NewAmsterdam Pharma Company N.V. Contract Liabilities
NewAmsterdam Pharma Company N.V. (NAMS) had Contract Liabilities of EUR 4.60 million as of 2023-06-30, per its 6-K filed 2023-08-07.
Discontinued › Notes
ifrs-full:ContractLiabilities · last filed 2023-08-07
- 2023-06-30: Contract Liabilities 4.60M EUR.
| Period end | Contract Liabilities |
|---|---|
| 2023-06-30 | 4.60M EUR 6-K · filed 2023-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |